Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862641 · ClinicalTrials.gov registry record · Phase 4
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,009
- Enrollment target
NCT00862641 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 1,009 participants.
The verdict
NCT00862641, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,009 participants
- Enrollment target
Study Summary
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
Interventions
- DRUG Placebo
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,009 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00862641
The ClinicalTrials.gov registry entry for NCT00862641 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,009 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00862641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00862641 about?
NCT00862641 is a clinical study titled "A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease". This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
What is the current status of trial NCT00862641?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,009 participants. The study started on 2009-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00862641?
The interventions under investigation include: Placebo (DRUG), Regadenoson (DRUG).
Who is sponsoring clinical trial NCT00862641?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.